NASDAQ:AKLI Akili (AKLI) Stock Price, News & Analysis → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Free AKLI Stock Alerts $0.42 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$0.42▼$0.4350-Day Range$0.21▼$0.4552-Week Range$0.19▼$1.67Volume7.04 million shsAverage Volume580,420 shsMarket Capitalization$33.11 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Akili alerts: Email Address Akili MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside851.0% Upside$4.00 Price TargetShort InterestHealthy0.92% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.23Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.53) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.47 out of 5 starsMedical Sector528th out of 928 stocksSurgical & Medical Instruments Industry63rd out of 100 stocks 3.5 Analyst's Opinion Consensus RatingAkili has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAkili has received no research coverage in the past 90 days.Read more about Akili's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.92% of the float of Akili has been sold short.Short Interest Ratio / Days to CoverAkili has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Akili has recently increased by 325.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkili does not currently pay a dividend.Dividend GrowthAkili does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AKLI. Previous Next 1.8 News and Social Media Coverage News SentimentAkili has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Akili this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for AKLI on MarketBeat in the last 30 days. This is a decrease of -87% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Akili to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akili insiders have not sold or bought any company stock.Percentage Held by Insiders10.10% of the stock of Akili is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.12% of the stock of Akili is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Akili's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Akili are expected to grow in the coming year, from ($0.53) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akili is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akili is -0.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkili has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Akili's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Akili Stock (NASDAQ:AKLI)Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.Read More AKLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKLI Stock News HeadlinesMay 29, 2024 | bizjournals.comAkili to be delisted after getting acquiredMay 29, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Akili, Inc. has obtained a Fair Price for its Public ShareholdersMay 29, 2024 | businesswire.comPureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health CompanyMay 29, 2024 | businesswire.comVirtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health CompanyMay 29, 2024 | americanbankingnews.comAkili, Inc. (NASDAQ:AKLI) Short Interest UpdateMay 15, 2024 | msn.comAkili reports Q1 results; suspends outlookMay 14, 2024 | investorplace.comAKLI Stock Earnings: Akili Beats EPS, Misses Revenue for Q1 2024May 14, 2024 | businesswire.comAkili Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 3, 2024 | bizjournals.comTherapeutic video game maker Akili lays off workers for third time in 16 monthsApril 30, 2024 | investorplace.comWhy Is Akili (AKLI) Stock Up 68% Today?April 30, 2024 | businesswire.comAkili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial ResultsMarch 11, 2024 | bizjournals.comDigital medicine maker Akili slashed executive pay in 2023March 3, 2024 | finance.yahoo.comAkili Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 1, 2024 | markets.businessinsider.comAkili (AKLI) Gets a Buy from TD CowenFebruary 29, 2024 | businesswire.comAkili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 28, 2024 | benzinga.comPreview: Akili's EarningsFebruary 28, 2024 | investing.comAkili's ADHD digital therapy seeks Japan approvalFebruary 27, 2024 | msn.comCrude Oil Gains 1%; US New Home Sales Increase In JanuaryFebruary 27, 2024 | businesswire.comPureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in JapanFebruary 26, 2024 | investorplace.comWhy Is Akili (AKLI) Stock Up 110% Today?February 26, 2024 | msn.comWhy Is Prescription Digital Medicine-Focused Akili Stock Trading Over 100% On Monday?February 26, 2024 | seekingalpha.comAkili's ADHD device submitted for Japanese approval, stock rallies 130%February 26, 2024 | finance.yahoo.comAkili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in JapanFebruary 26, 2024 | businesswire.comAkili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx® for Pediatric ADHD Patients in JapanFebruary 21, 2024 | finance.yahoo.comAkili Announces Release Date for Fourth Quarter and Full Year 2023 Financial Results, Provides Investor Communications and Board and Corporate Governance UpdatesSee More Headlines Receive AKLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akili and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/01/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:AKLI CUSIPN/A CIK1850266 Webwww.akiliinteractive.com Phone650-931-6236FaxN/AEmployees68Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$4.00 Low Stock Price Target$4.00 Potential Upside/Downside+851.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,490,000.00 Net Margins-2,492.04% Pretax Margin-2,489.32% Return on Equity-79.93% Return on Assets-59.16% Debt Debt-to-Equity Ratio0.08 Current Ratio5.80 Quick Ratio5.80 Sales & Book Value Annual Sales$1.95 million Price / Sales17.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book0.66Miscellaneous Outstanding Shares78,716,000Free Float70,766,000Market Cap$33.11 million OptionableOptionable Beta1.70 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Walter Edward Martucci II (Age 41)Ph.D., Co-Founder & Chairman Comp: $759.1kMr. Matthew Franklin M.B.A. (Age 50)President, CEO & Director Comp: $639.13kDr. Adam Gazzaley M.D. (Age 54)Ph.D., Co-Founder, Chief Science Advisor & Director Comp: $126.45kMs. Jacqueline L. Studer J.D. (Age 65)Chief Legal Officer, General Counsel & Secretary Comp: $559.55kMs. Caty ReidVP of Marketing & CommunicationsDr. Scott H. Kollins Ph.D.Chief Medical OfficerMr. Jonathan David (Age 46)Chief Product Officer More ExecutivesKey CompetitorsGetaroundNYSE:GETRSemper Paratus AcquisitionNASDAQ:LGSTKORU Medical SystemsNASDAQ:KRMDBlueRiver AcquisitionNYSE:BLUABrainsWayNASDAQ:BWAYView All CompetitorsInsiders & InstitutionsLongitude Cayman Ltd.Bought 150,000 shares on 5/10/2024Ownership: 0.445%Walter Edward Martucci IISold 2,353 sharesTotal: $2,470.65 ($1.05/share)Matthew FranklinSold 1,728 sharesTotal: $1,814.40 ($1.05/share)Jacqueline StuderSold 1,130 sharesTotal: $1,186.50 ($1.05/share)Santosh ShanbhagSold 830 sharesTotal: $871.50 ($1.05/share)View All Insider TransactionsView All Institutional Transactions AKLI Stock Analysis - Frequently Asked Questions Should I buy or sell Akili stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akili in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKLI shares. View AKLI analyst ratings or view top-rated stocks. What is Akili's stock price target for 2024? 1 Wall Street analysts have issued 1-year price targets for Akili's stock. Their AKLI share price targets range from $4.00 to $4.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 851.0% from the stock's current price. View analysts price targets for AKLI or view top-rated stocks among Wall Street analysts. How have AKLI shares performed in 2024? Akili's stock was trading at $0.4871 at the start of the year. Since then, AKLI shares have decreased by 13.7% and is now trading at $0.4206. View the best growth stocks for 2024 here. Are investors shorting Akili? Akili saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 487,700 shares, an increase of 325.6% from the April 30th total of 114,600 shares. Based on an average daily volume of 3,760,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.9% of the company's stock are short sold. View Akili's Short Interest. When is Akili's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our AKLI earnings forecast. How were Akili's earnings last quarter? Akili, Inc. (NASDAQ:AKLI) announced its earnings results on Tuesday, May, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. The company had revenue of $0.38 million for the quarter. Akili had a negative net margin of 2,492.04% and a negative trailing twelve-month return on equity of 79.93%. Who are Akili's major shareholders? Akili's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Longitude Cayman Ltd. (0.45%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jacqueline Studer, Matthew Franklin, Santosh Shanbhag and Walter Edward Martucci II. View institutional ownership trends. How do I buy shares of Akili? Shares of AKLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AKLI) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akili, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
